News

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.

Paylocity’s (NASDAQ:PCTY) Q1 Sales Beat Estimates, Provides Encouraging Quarterly Revenue Guidance

Payroll and human resources software provider, Paylocity (NASDAQ:PCTY) announced better-than-expected revenue in Q1 CY2025, with sales up 13.3% year on year to $454.5 million. Guidance for next quarter’s revenue was better than expected at $388 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $2.43 per share was 14.8% above analysts’ consensus estimates.

Five9 (NASDAQ:FIVN) Exceeds Q1 Expectations

Call center software provider Five9 (NASDAQ: FIVN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 13.2% year on year to $279.7 million. The company expects next quarter’s revenue to be around $275 million, close to analysts’ estimates. Its non-GAAP profit of $0.64 per share was 32.5% above analysts’ consensus estimates.

Trump says it's Biden's economy, but businesses and economists beg to differ

When the stock market was climbing in January 2024, Donald Trump knew exactly who deserved credit: He did. Nearly a year before his return to the White House, he declared on his Truth Social platform that investors were celebrating his lead in the polls against President Joe Biden. When the stock market fell Wednesday on news that the American economy had gone backward during the first three months of 2025, Trump knew exactly who to blame: Biden.

Roku (NASDAQ:ROKU) Surprises With Q1 Sales But Quarterly Revenue Guidance Significantly Misses Expectations

Streaming TV platform Roku (NASDAQ: ROKU) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 15.8% year on year to $1.02 billion. On the other hand, next quarter’s revenue guidance of $1.07 billion was less impressive, coming in 1.6% below analysts’ estimates. Its GAAP loss of $0.19 per share was 27.4% above analysts’ consensus estimates.